Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.
In this randomised double-blind parallel study, we compared the efficacy of labetalol and atenolol in a group of black (n = 33) and white (n = 34) hypertensives with uncomplicated essential hypertension after obtaining pretreatment renin profiles. After single-blind placebo (14-21 days), patients with standing diastolic BP between 105-119 mmHg were randomised to receive either labetalol (100-800 mg twice daily) or atenolol (50-100 mg once daily) to achieve a DBP less than 90 mmHg. Dosage titration occurred at weekly intervals for labetalol and biweekly for atenolol. The supine BP decrease with atenolol was -18/-14 vs. -6/-6 mmHg in whites vs. blacks respectively. With labetalol, it was -13/-12 in whites and -2/-7 mmHg in blacks. Standing BPs were: -19/-14 vs. -4/-5, whites vs. blacks with atenolol and -17/-17 vs. -19/-9 mmHg with labetalol. Neither labetalol nor atenolol was as effective in black compared with white hypertensives. The atenolol but not labetalol BP response was positively correlated with pretreatment renin values.
Department of Medicine, Medical College of Virginia, Commonwealth University, Richmond.
J T
JT
Wright
D J
DJ
DiPette
R P
RP
Goodman
R
R
Townsend
J M
JM
McKenney
D001262:Atenolol / Q000592:standards* / Q000627:therapeutic use; D044383:Black People; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000208:ethnology; D007741:Labetalol / Q000592:standards* / Q000627:therapeutic use; D008875:Middle Aged; D012083:Renin / Q000097:blood*; D044465:White People
D001262:Atenolol; D012083:Renin; D007741:Labetalol